Background: Biological agents such as anti-tumor necrosis factor (TNF) induce remission in ulcerative colitis. There is however no consensus regarding the discontinuation of this treatment.
Aim: The aim of this study is to assess whether clinical parameters and mucosal cytokine mRNAs in healed colonic mucosa can predict long-term remission in ulcerative colitis following discontinuation of infliximab (IFX) therapy.
Methods: The prospective Tromsø Inflammatory Bowel Disease (IBD) Study is based on an intensified induction treatment algorithm with IFX to achieve disease remission. Following clinical and endoscopic remission, IFX treatment was discontinued, and follow-up until relapse was performed. Patients who achieved clinical and endoscopic remission following an induction course of IFX were included. Expression levels of TNF alpha (TNF), interferon gamma (IFNG), interleukin (IL) 6 (IL6), IL17A, IL23, and transforming growth factor beta (TGFB) were quantified by real-time PCR in mucosal biopsies obtained at colonoscopy. Remission was defined as Ulcerative Colitis Disease Activity Index (UCDAI) below 3, and an endoscopic sub-score of 0-1. Relapse was defined as UCDAI score >3 and endoscopic sub-score >1. Mucosal cytokine transcript levels from 20 non-IBD patients with a normal colonoscopy served as control group.
Results: Of the 45 patients included, twenty patients (44%) had normalized levels of mucosal TNF expression at the time of mucosal healing, whereas 35 of 42 (83%) had normalized IL17A expression levels, and 31 of 36 (86%) had normalized IFNG expression levels. The median time to relapse was 8months (range 4-12). Normalization of TNF gene expression predicted 20months (1-39) relapse-free survival after withdrawal of IFX compared to 5months (3-7) in the group with elevated TNF expression. Mucosal expression levels of IL17A, IL23, IFNG, TGFB, IL6 did not predict long-term remission (>12months)
Conclusion: Normalization of mucosal TNF predicts long-term remission after discontinuation of IFX.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cyto.2015.12.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Programmable Food-Derived Peptide Coassembly Strategies for Boosting Targeted Colitis Therapy by Enhancing Oral Bioavailability and Restoring Gut Microenvironment Homeostasis.
ACS Nano
January 2025
Jilin Provincial Key Laboratory of Nutrition and Functional Food, College of Food Science and Engineering, Jilin University, Changchun 130062, China.
Orally targeting nanostrategies of multiple nutraceuticals have attracted increasing attention in ulcerative colitis (UC) therapy for superior patient compliance, cost-effectiveness, and biocompatibility. However, the actual targeting delivery and bioefficacy of nutraceuticals are extremely restricted by their poor solubility, interior gastrointestinal retention, and base permeability. Herein, we developed controllable colon-targeting nanoparticles (NPs) composed of a quaternary ammonium chitosan (HTCC) shell and succinic acid-modified γ-cyclodextrin (SACD) core for precise UC treatment.
View Article and Find Full Text PDFEditorial: Where to Start in Ulcerative Colitis?
Aliment Pharmacol Ther
January 2025
Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Bacterial attachment and junctional transport function in induced apical-out polarized and differentiated canine intestinal organoids.
Front Vet Sci
December 2024
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Dogs are increasingly recognized as valuable large animal models for understanding human intestinal diseases, as they naturally develop conditions similar to those in humans, such as Enterohemorrhagic , , inflammatory bowel disease, and ulcerative colitis. Given the similarity in gut flora between dogs and humans, canine intestinal models are ideal for translational research. However, conventional extracellular matrix-embedded organoids present challenges in accessing the lumen, which is critical for gut function.
View Article and Find Full Text PDFPolysaccharides derived from golden mushroom ( Fr.) modulate gut microbiota and enhance intestinal barrier function to ameliorate dextran sulfate sodium-induced colitis in mice.
Front Pharmacol
December 2024
Department of Biotechnology, College of Basic Medical Science, Dalian Medical University, Dalian, China.
Introduction: Inflammatory bowel disease (IBD), including ulcerative colitis, is marked by intestinal barrier disruptions, immune system dysregulation, and an imbalance in the gut microbiota. The golden chanterelle mushroom, Fr., a popular edible mushroom, has shown potential therapeutic benefits.
View Article and Find Full Text PDFRelationship between SIBO and other bowel diseases and a common eating pattern for them. Part III.
Ann Agric Environ Med
September 2024
Higher School of Health Promotion, Kraków, Poland.
Introduction And Objective: Conditions resulting from diseases of the brain-gut axis and gum-gut axis show many mutual, often bi-directional interrelationships. The accompanying quantitative and/or qualitative disorders of intestinal microflora may be effectively regulated by implementation of a properly adjusted diet therapy. The aim of the study is to investigate whether there is a relationship between small intestinal bacterial overgrowth (SIBO), and irritable bowel syndrome (IBS), and non-specific inflammatory bowel diseases (IBD), as well as indications for the mode of nutrition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!